Médunik Canada Secures Exclusive Distribution Rights for INCRELEX® (Mecasermin) in Canada, Bolstering Access for Children with Severe Primary IGF-1 Deficiency
Key Insights
Médunik Canada (search) has become the exclusive Canadian distributor of INCRELEX® (mecasermin), a recombinant human IGF-1 therapy for children and adolescents aged 2 to 18 with severe primary IGF-1 deficiency (SPIGFD).
SPIGFD is an ultra-rare endocrine disorder in which the body cannot produce adequate IGF-1, leading to severely impaired growth and significant short stature without appropriate treatment.
The distribution agreement was established in partnership with ESTEVE (search), a global pharmaceutical company, recognizing Médunik Canada (search)'s expertise in rare diseases and patient-centered support programs.
Médunik Canada (search), a Canadian-owned pharmaceutical company within the Duchesnay Pharmaceutical Group (search), announced on July 14, 2026, that it has become the exclusive distributor of INCRELEX® (mecasermin) in Canada. The agreement, forged in partnership with global pharmaceutical company ESTEVE (search), aims to ensure continuity of supply for Canadian patients living with severe primary insulin-like growth factor-1 deficiency (search) (SPIGFD), an ultra-rare endocrine disorder.
Mecasermin is a recombinant human insulin-like growth factor-1 (rhIGF-1) therapy indicated for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed SPIGFD. The condition is characterized by the body's inability to produce adequate levels of IGF-1, a hormone essential for normal childhood growth. Without appropriate treatment, affected children may experience severely impaired growth, leading to significant short stature and its associated physical and emotional challenges.
"Becoming the exclusive distributor of INCRELEX® in Canada is a natural extension of Médunik Canada (search)'s mission to improve the lives of patients with rare conditions," said Carla Létourneau, Director of Marketing Strategy at Médunik Canada. "Children living with severe primary IGF-1 deficiency face unique diagnostic and treatment challenges. We are proud to partner with ESTEVE (search) to ensure continued access to this important therapy and to support families throughout their treatment journey."
ESTEVE (search), which focuses on delivering highly specialized treatments, selected Médunik Canada (search) as its national distribution partner based on the company's established expertise in rare diseases and its patient-centered support programs. As part of the transition, Médunik Canada will maintain the existing patient support program, helping to ensure uninterrupted services for patients and caregivers.
Dr. Cheri Deal, Ph.D., M.D., Pediatric Endocrinologist at CHU Sainte-Justine, underscored the importance of timely intervention. "Early and accurate diagnosis of severe primary IGF-1 deficiency is critical to achieving optimal outcomes," said Dr. Deal. "Having a therapy like INCRELEX®, combined with comprehensive patient support and education, makes a meaningful difference for children who have limited treatment options. This partnership represents an important step forward for patients and healthcare providers."
Through this collaboration, Médunik Canada (search) and ESTEVE (search) reaffirm their shared commitment to supporting patients with rare diseases and the healthcare professionals who serve them across Canada. Médunik Canada, founded in December 2009 and part of Duchesnay Pharmaceutical Group (search), provides access to orphan drugs through strategic global partnerships as well as domestic and international research and development projects.